Amyloid imaging in vivo: implications for Alzheimer's disease management

Bibliography

• JORM AF: Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur. Arch. Psychiatry Clin. Neurosci. (1991) 240:218-222.
   PubMed Web of Science ®Google Scholar
• Canadian study of health and ageing: study methods and prevalence of dementia. CMAJ (1994) 150(6):899-913.
   PubMed Web of Science ®Google Scholar
• MCKHANN G, DRACHMAN D, FOLSTEIN M, KATZMAN R, PRICE D, STADLAN EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology (1984) 34(7):939-944.
   PubMed Web of Science ®Google Scholar
• STEVENS T, LIVINGSTON G, KITCHEN G, MANELA M, WALKER Z, KATONA C: Islington study of dementia subtypes in the community. Br. J. Psychiatry (2002) 180:270-276.
   PubMed Web of Science ®Google Scholar
• ROMÁN GC, TATEMICHI TK, ERKINJUNTTI T et al.: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International workshop. Neurology (1993) 43(2):250-260.
   PubMed Web of Science ®Google Scholar
• MCKEITH IG, DICKSON DW, LOWE J et al.: Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology (2005) 65(12):1863-1872.
   PubMed Web of Science ®Google Scholar
• NEARY D, SNOWDEN JS, GUSTAFSON L et al.: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology (1998) 51(6):1546-1554.
   PubMed Web of Science ®Google Scholar
• AMICI S, GORNO-TEMPINI ML, OGAR JM, DRONKERS NF, MILLER BL: An overview on primary progressive aphasia and its variants. Behav. Neurol. (2006) 17(2):77-87.
   PubMed Web of Science ®Google Scholar
• FILLIT H, HILL JW, FUTTERMAN R: Healthcare utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam. Med. (2002) 34(7):528-535.
   PubMed Web of Science ®Google Scholar
• SILVERMAN DHS: Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J. Nucl. Med. (2004) 45(4):594-607.
   PubMed Web of Science ®Google Scholar
• LUTZ W, SANDERSON W, SCHERBOV S: The end of world population growth. Nature (2001) 412:543-545.
   PubMed Web of Science ®Google Scholar
• ROGERS SL, FRIEDHOFF LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open-label extension study. Eur. Neuropsychopharmacol. (1998) 8(1):67-75.
   PubMed Web of Science ®Google Scholar
• IMBIMBO BP, VERDELLI G, MARTELLI P, MARCHESINI D: Two-year treatment of Alzheimer's disease with eptastigmine. The eptastigmine study group. Dement. Geriatr. Cogn. Disord. (1999) 10(2):139-147.
   PubMed Web of Science ®Google Scholar
• COYLE J, KERSHAW P: Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol. Psychiatry (2001) 49(3):289-299.
   PubMed Web of Science ®Google Scholar
• FAGO JP: Dementia: causes, evaluation, and management. Hosp. Pract. (Minneap.) (2001) 36(1):59-69.
   Web of Science ®Google Scholar
• GELDMACHER DS, PROVENZANO G, MCRAE T, MASTEY V, IENI JR: Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J. Am. Geriatr. Soc. (2003) 51(7):937-944.
   PubMed Web of Science ®Google Scholar
• COREY-BLOOM J, ANAND R, VEACH J; for the ENA 713 B352 STUDY GROUP: A randomized trial evaluating the efficacy and safety of ENA 713 rivastigmine tartrate, a new acetylcholinesterase inhibitor, in patients with mild-to-moderately severe AD. Int. J. Psychopharmacol. (1998) 1:55-65.
   Google Scholar
• RASKIND MA, PESKIND ER, WESSEL T, YUAN W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The galantamine USA-1 study group. Neurology (2000) 54(12):2261-2268.
   PubMed Web of Science ®Google Scholar
• DOODY RS, GELDMACHER DS, GORDON B, PERDOMO CA, PRATT RD; DONEPEZIL STUDY GROUP: Open-label, multicenter, Phase III extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch. Neurol. (2001) 58(3):427-433.
   PubMed Web of Science ®Google Scholar
• MOSCONI L: Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging (2005) 32(4):486-510.
   PubMed Web of Science ®Google Scholar
• DOUGALL NJ, BRUGGINK S, EBMEIER KP: Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am. J. Geriatr. Psychiatry (2004) 12(6):554-570.
   PubMed Web of Science ®Google Scholar
• ARNOLD SE, HYMAN BT, FLORY J et al.: The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex (1991) 1:103-116.
   PubMed Web of Science ®Google Scholar
• BRAAK H, BRAAK E: Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Ageing (1997) 18:351-357.
   PubMed Web of Science ®Google Scholar
• HARDY J, SELKOE DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 297(5580):353-356.
   PubMed Web of Science ®Google Scholar
• THAL DR, RUB U, ORANTES M, BRAAK H: Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology (2002) 58(12):1791-1800.
   PubMed Web of Science ®Google Scholar
• BRAAK H, BRAAK E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) (1991) 82:239-259.
   PubMed Web of Science ®Google Scholar
• DELACOURTE A, DAVID JP, SERGEANT N et al.: The biochemical pathway of neurofibrillary degeneration in ageing and Alzheimer's disease. Neurology (1999) 52(6):1158-1165.
   PubMed Web of Science ®Google Scholar
• IQBAL K, ALONSO ADEL C, CHEN S et al.: Tau pathology in Alzheimer's disease and other tauopathies. Biochim. Biophys. Acta (2005) 1739(2-3):198-210.
   PubMed Web of Science ®Google Scholar
• TERRY RD, MASLIAH E, SALMON DP et al.: Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. (1991) 30(4):572-580.
   PubMed Web of Science ®Google Scholar
• MASLIAH E, MALLORY M, ALFORD M et al.: Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology (2001) 56(1):127-129.
   PubMed Web of Science ®Google Scholar
• NICHOLS L, PIKE VW, CAI L, INNIS RB: Imaging and in vivo quantitation of β-amyloid: an exemplary biomarker for Alzheimer's disease? Biol. Psychiatry (2006) 59(10):940-947.
   PubMed Web of Science ®Google Scholar
• CAI L, INNIS RB, PIKE VW: Radioligand development for PET imaging of β-amyloid (Aβ) – current status. Curr. Med. Chem. (2007) 14(1):19-52.
   PubMed Web of Science ®Google Scholar
• MONTALTO MC, FARRAR G, HEHIR CT: Fibrillar and oligomeric β-amyloid as distinct local biomarkers for Alzheimer's disease. Ann. NY Acad. Sci. (2007) 1097:239-258.
   PubMed Web of Science ®Google Scholar
• SERPELL LC: Alzheimer's amyloid fibrils: structure and assembly Biochim. Biophys. Acta (2000) 1502(1):16-30.
   PubMed Web of Science ®Google Scholar
• BIBL M, MOLLENHAUER B, LEWCZUK P et al.: Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psychiatry (2007) 12(7):671-680.
   PubMed Web of Science ®Google Scholar
• QI-TAKAHARA Y, MORISHIMA-KAWASHIMA M, TANIMURA Y et al.: Longer forms of amyloid β protein: implications for the mechanism of intramembrane cleavage by γ-secretase. J. Neurosci. (2005) 25(2):436-445.
   PubMed Web of Science ®Google Scholar
• KNUDSEN KA, ROSAND J, KARLUK D, GREENBERG SM: Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology (2001) 56(4):537-539.
   PubMed Web of Science ®Google Scholar
• HARDY J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. (1997) 20:154-159.
   PubMed Web of Science ®Google Scholar
• HUANG TH, YANG DS, FRASER PE, CHAKRABARTTY A: Alternate aggregation pathways of the Alzheimer β-amyloid peptide. An in vitro model of preamyloid. J. Biol. Chem. (2000) 275(46):36436-36440.
   PubMed Web of Science ®Google Scholar
• PETERSEN RC, PARISI JE, DICKSON DW et al.: Neuropathologic features of amnestic mild cognitive impairment. Arch. Neurol. (2006) 63(5):665-672.
   PubMed Web of Science ®Google Scholar
• BERG L, MCKEEL DW, MILLER P et al.: Clinicopathologic studies in cognitively healthy ageing and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. (1998) 55:326-335.
   PubMed Web of Science ®Google Scholar
• HARTLEY DM, WALSH DM, YE CP et al.: Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. (1999) 19(20):8876-8884.
   PubMed Web of Science ®Google Scholar
• WALSH DM, KLYUBIN I, FADEEVA JV et al.: Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 416(6880):535-539.
   PubMed Web of Science ®Google Scholar
• BITAN G, KIRKITADZE MD, LOMAKIN A, VOLLERS SS, BENEDEK GB, TEPLOW DB: Amyloid β-protein (Aβ) assembly: Aβ 40 and Aβ 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA (2003) 100:330-335.
   PubMed Web of Science ®Google Scholar
• KLEIN WL, STINE WB Jr, TEPLOW DB: Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Ageing (2004) 25:569-580.
   PubMed Web of Science ®Google Scholar
• GORMAN PM, YIP CM, FRASER PE, CHAKRABARTTY A: Alternate aggregation pathways of the Alzheimer β-amyloid peptide: Aβ association kinetics at endosomal pH. J. Mol. Biol. (2003) 325:743-757.
   PubMed Web of Science ®Google Scholar
• WALSH DM, HARTLEY DM, KUSUMOTO Y et al.: Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. (1999) 274:25945-25952.
   PubMed Web of Science ®Google Scholar
• CLEARY JP, WALSH DM, HOFMEISTER JJ et al.: Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. (2005) 8:79-84.
   PubMed Web of Science ®Google Scholar
• SHOGHI-JADID K, SMALL GW, AGDEPPA ED et al.: Localization of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer's disease. Am. J. Geriatr. Psychiatry (2002) 10(1):24-35.
   PubMed Web of Science ®Google Scholar
• KLUNK WE, ENGLER H, NORDBERG A et al.: Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. (2004) 55(3):306-319.
   PubMed Web of Science ®Google Scholar
• VERHOEFF NPLG, WILSON AA, TAKESHITA S et al.: In vivo imaging of Alzheimer's disease β-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry (2004) 12:584-595.
   PubMed Web of Science ®Google Scholar
• BAUER M, LANGER O, DAL-BIANCO P et al.: A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clin. Pharmacol. Ther. (2006) 80(3):216-227.
   PubMed Web of Science ®Google Scholar
• KUDO Y, OKAMURA N, FURUMOTO S et al.: 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. (2007) 48(4):553-561.
   PubMed Web of Science ®Google Scholar
• MATHIS C, LOPRESTI B, MASON N et al.: Comparison of the amyloid imaging agents [F-18]3′-F-PIB and [C-11]PIB in Alzheimer's disease and control subjects. J. Nucl. Med. (2007) 48(Suppl. 2):P56.
   Google Scholar
• CAI L, LIOW JS, MORSE C et al.: [18F]FMS-IMPY and [18F]FES-IMPY as potential radioligands for imaging brain β-amyloid. J. Nucl. Med. (2007) 48(Suppl. 2):P130.
   Google Scholar
• WANG C, EASWARAMOORTHY B, PICHIKA R, COLLINS D, HEAD E, MUKHERJEE J: 18F-FBM: a new PET radiotracer for imaging β-amyloid plaques and neurofibrillary tangles. J. Nucl. Med. (2006) 47(Suppl. 1):P217.
   Google Scholar
• SERDONS K, TERWINGHE C, VERMAELEN P, KUNG H, BORMANS G, VERBRUGGEN A: 6-Methoxy-2-(4′-[18F]fluorophenyl)1,3-benzothiazole and 6-methyl-2(4′-[18F]fluorophenyl)-1,3-benzothiazole as potential amyloidimaging agents. J. Nucl. Med. (2006) 47(Suppl. 1):P31.
   Google Scholar
• CHANDRA R, STEPHENSON K, KUNG MP, HOU C, KUNG H: 2-Arylbenzothiazole derivatives for β-amyloid plaque imaging. J. Nucl. Med. (2006) 47(Suppl. 1):P217.
   Google Scholar
• ZHANG W, KUNG MP, OYA S, HOU C, KUNG H: F-18 labeled PEG stilbene derivatives as PET imaging agents for Alzheimer's disease. J. Nucl. Med. (2006) 47(Suppl. 1):P218.
   Google Scholar
• CHANDRA R, OYA S, KUNG MP, HOU C, KUNG H: 18F-Pegylated alkynes as potential PET imaging agents for Alzheimer's disease. J. Nucl. Med. (2007) 48(Suppl. 2):P301.
   Google Scholar
• SHOUP T, ELMALEH D, JIN Y et al.: [N-2[18F]fluoropropyl]2-(4′(methylamino)phenyl)-6-hydroxybenzothiazole for potential Aβ amyloid imaging. J. Nucl. Med. (2007) 48(Suppl. 2):P299.
   Google Scholar
• LEE YS, JEONG J, CHANG Y et al.: Syntheses and evaluation of 2-(4′-[18F]fluoromethylphenyl)benzothazole and benzoxazole derivatives as PET agents for β-amyloid (Aβ) plaque imaging. J. Nucl. Med. (2007) 48(Suppl. 2):P301.
   Google Scholar
• PATEL P, COLLINS D, NISTOR M, EASWARAMOORTHY B, HEAD E, MUKHERJEE J: 18F-fluoropropyl curcumin: a potential PET tracer for imaging inflammation and Aβ-plaques. J. Nucl. Med. (2007) 48(Suppl. 2):P22.
   PubMed Web of Science ®Google Scholar
• STEPHENSON K, KUNG H, KUNG MP, HOU C: Styrylbenzoxazole derivatives for β-amyloid plaque imaging. J. Nucl. Med. (2006) 47(Suppl. 1):P497.
   Google Scholar
• BORNEBROEK M, VERZIJLBERGEN JF, HAAN J et al.: Potential for imaging cerebral amyloid deposits using 123I-labeled serum amyloid P component and SPET. Nucl. Med. Commun. (1996) 17:929-933.
   PubMed Web of Science ®Google Scholar
• MAREK K, JENNINGS D, KOREN A, TAMAGNAN G, SKOVRONSKY D, SEIBYL J: [I-123]IMPY imaging to assess β-amyloid burden in Alzheimer's disease. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):10.
   Google Scholar
• SHIH-YING L, CHENG-XIANG Y, KANG-WEI C et al.: Syntheses of 123I-IOBOX for binding β-amyloid plaques in the Tg2576 transgenic mice. J. Nucl. Med. (2006) 47(Suppl. 1):P547.
   Google Scholar
• KULKARNI P, RONEY C, ARORA V et al.: Imaging AD plaques in transgenic and animal model of AD with radioiodinated clioquinol. J. Nucl. Med. (2006) 47(Suppl. 1):P218.
   Google Scholar
• ONO M, MAYA Y, HARATAKE M, NAKAYAMA M: Synthesis and characterization of styrylchomone derivatives as amyloid imaging agents. J. Nucl. Med. (2006) 47(Suppl. 1):P498.
   Google Scholar
• ONO M, HARATAKE M, NAKAYAMA M: Novel chalcones as probes for in vivo detecting of β-amyloid plaques in Alzheimer's disease. J. Nucl. Med. (2007) 48(Suppl. 2):P300.
   Google Scholar
• QU W, KUNG MP, HOU C et al.: Novel iodinated styrylpyridines for SPECT imaging of β-amyloid plaques. J. Nucl. Med. (2007) 48(Suppl. 2):P303.
   Google Scholar
• QU W, KUNG MP, HOU C, KUNG H: Bisphenyltriazoles as potential imaging agents for Alzheimer's disease. J. Nucl. Med. (2007) 48(Suppl. 2):P129.
   Google Scholar
• QU W, KUNG MP, HOU C, KUNG H: Radioiodinated alkynes as potential SPECT imaging agents for Alzheimer's disease. J. Nucl. Med. (2007) 48(Suppl. 2):P302.
   Google Scholar
• KANDIMALLA KK, WENGENACK TM, CURRAN GL, GILLES EJ, PODUSLO JF: Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild type and Alzheimer's disease transgenic mice. J. Pharmacol. Exp. Ther. (2007) 322(2):541-549.
   PubMed Web of Science ®Google Scholar
• SIGURDSSON EM, WADGHIRI YZ, MOSCONI L et al.: A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Ageing (2007):[Epub ahead of print].
   PubMedGoogle Scholar
• NAKADA T, MATSOZAWA H, IGARASHI H, FUJI Y, KWEE I: Direct visualization of senile plaques of patients in vivo by magnetic resonance microscopy on a 7 T clinical system. Presentation at the 28 April – 5 May 2007, Annual Meeting of the American Academy of Neurology, Boston, MA, USA. Neurology (2007) 68(Suppl. 1):A98.
   Google Scholar
• VERHOEFF NPLG: Ligands for neuroreceptor imaging by positron or single-photon emission tomography. In: Nuclear Medicine in Clinical Diagnosis and Treatment, (3rd Edition). Ell PJ, Gambhir SS (Eds), Churchill Livingstone, New York, NY, USA (2004):1275-1294.
   Google Scholar
• FRIEDLAND RP, KALARIA R, BERRIDGE M et al.: Neuroimaging of vessel amyloid in Alzheimer's disease. Ann. NY Acad. Sci. (1997) 826:242-247.
   PubMed Web of Science ®Google Scholar
• SMALL GW, KEPE V, ERCOLI LM et al.: PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. (2006) 355(25):2652-2663.
   PubMed Web of Science ®Google Scholar
• SMALL GW, AGDEPPA ED, KEPE V, SATYAMURTHY N, HUANG SC, BARRIO JR: In vivo brain imaging of tangle burden in humans. J. Mol. Neurosci. (2002) 19(3):323-327.
   PubMed Web of Science ®Google Scholar
• YE L, MORGENSTERN JL, GEE AD, HONG G, BROWN J, LOCKHART A: Delineation of positron emission tomography imaging agent binding sites on β-amyloid peptide fibrils. J. Biol. Chem. (2005) 280(25):23599-23604.
   PubMed Web of Science ®Google Scholar
• SMALL GW, KEPE V, HUANG SC et al.: In vivo brain imaging of tau aggregation in frontal temporal dementia using [F-18]FDDNP positron emission tomography. Presentation at the 9th International Conference on Alzheimer's Disease and Related Disorders 2004. Neurobiol. Ageing (2004) 25(Suppl. S2):S288-S289.
   Google Scholar
• BOXER AL, RABINOVICI GD, KEPE V et al.: Amyloid imaging in distinguishing atypical prion disease from Alzheimer's disease. Neurology (2007) 69(3):283-290.
   PubMed Web of Science ®Google Scholar
• KEPE V, GHETTI B, BRESJANAC M et al.: [F-18]FDDNP PET imaging of prion pathology in Gerstmann-Sträusller-Scheinker disease. J. Nucl. Med. (2007) 48(Suppl. 2):P172.
   Google Scholar
• AGDEPPA ED, KEPE V, PETRI A et al.: In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. Neuroscience (2003) 117(3):723-730.
   PubMed Web of Science ®Google Scholar
• SHOGHI-JADID K, BARRIO JR, KEPE V et al.: Imaging β-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl. Med. Biol. (2005) 32(4):337-351.
   PubMed Web of Science ®Google Scholar
• DEKOSKY ST, MATHIS CA, PRICE JC et al.: Correlation of in vivo PIB retention and postmortem Aβ levels: a case study. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):14.
   Google Scholar
• ENGLER H, FORSBERG A, ALMKVIST O et al.: Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 129(Part 11):2856-2866.
   PubMed Web of Science ®Google Scholar
• EDISON P, ARCHER HA, HINZ R et al.: Amyloid, hypometabolism, and cognition in Alzheimer's disease: an [11C]PIB and [18F]FDG PET study. Neurology (2007) 68(7):501-508.
   PubMed Web of Science ®Google Scholar
• MARK RJ, PANG Z, GEDDES JW, UCHIDA K, MATTSON MP: Amyloid β-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. (1997) 17(3):1046-1054.
   PubMed Web of Science ®Google Scholar
• COPANI A, KOH JY, COTMAN CW: β-Amyloid increases neuronal susceptibility to injury by glucose deprivation. Neuroreport (1991) 2(12):763-765.
   PubMed Web of Science ®Google Scholar
• DECARLI CS, ATACK JR, BALL MJ et al.: Postmortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional metabolic rates for glucose during life in AD patients. Neurodegeneration (1992) 1:113-121.
   Google Scholar
• LOPRESTI BJ, KLUNK WE, MATHIS CA et al.: Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J. Nucl. Med. (2005) 46(12):1959-1972.
   PubMed Web of Science ®Google Scholar
• PRICE JC, KLUNK WE, LOPRESTI BJ et al.: Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J. Cereb. Blood Flow Metab. (2005) 25(11):1528-1547.
   PubMed Web of Science ®Google Scholar
• ZHOU Y, YE W, BRASIC J, ALEXANDER M, RESNICK SM, WONG DF: Evaluation of data acquisition time on the quantification of [11C]PIB PET. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):9.
   Google Scholar
• KEMPPAINEN NM, AALTO S, WILSON IA et al.: Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer's disease. Neurology (2006) 67(9):1575-1580.
   PubMed Web of Science ®Google Scholar
• ZIOLKO SK, WEISSFELD LA, KLUNK WE et al.: Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage (2006) 33(1):94-102.
   PubMed Web of Science ®Google Scholar
• TESTA C, LAAKSO MP, SABATTOLI F et al.: A comparison between the accuracy of voxel-based morphometry and hippocampal volumetry in Alzheimer's disease. J. Magn. Reson. Imaging (2004) 19(3):274-282.
   PubMed Web of Science ®Google Scholar
• CHOW TW, TAKESHITA S, HONJO K et al.: Comparison of manual and semiautomated delineation of regions of interest for radioligand PET imaging analysis. BMC Nucl. Med. (2007) 7:2.
   PubMedGoogle Scholar
• TOLBOOM N, YAQUB M, VAN DER FLIER W et al.: Imaging β-amyloid deposition in vivo: quantitative comparison between [18F]FDDNP and [11C]PIB. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):16.
   Google Scholar
• OKAMURA N, KUDO Y, FURUMOTO S et al.: In vivo imaging of amyloid plaques in the brain: [11C]BF-227 PET study. The 6th Annual Meeting of the International College of Geriatric Psychoneuropharmacology. Hiroshima, Japan (3 – 6 October 2006). Jpn Program. Abstr. (2006):135.
   Google Scholar
• KUDO Y: Development of amyloid imaging PET probes for an early diagnosis of Alzheimer's disease. Minim. Invasive Ther. Allied Technol. (2006) 15(4):209-213.
   PubMed Web of Science ®Google Scholar
• ARAI H, OKAMURA N, TASHIRO M, YANAI K, KUDO Y: In vivo detection of amyloid deposits in normals, mild cognitive impairment and Alzheimer's disease patients using [11C]BF-227 and PET. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):15.
   Google Scholar
• NEWBERG A, WINTERING N, CLARK C et al.: Use of 123I IMPY SPECT to differentiate Alzheimer's disease from controls. J. Nucl. Med. (2006) 47(Suppl. 1):P78.
   Google Scholar
• SONG P, SERGE B, SARRADIN P et al.: IMPY, a β-amyloid imaging probe for prion detection. J. Nucl. Med. (2006) 47(Suppl. 1):P134.
   Google Scholar
• ROWE CC, NG S, MULLIGAN R et al.: First results from human studies of a novel F-18 PET ligand for brain β-amyloid imaging. J. Nucl. Med. (2007) 48(Suppl. 2):P57.
   Google Scholar
• AISEN PS: The development of antiamyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors. CNS Drugs (2005) 19(12):989-996.
   PubMed Web of Science ®Google Scholar
• KLAFKI HW, STAUFENBIEL M, KORNHUBER J, WILTFANG J: Therapeutic approaches to Alzheimer's disease. Brain (2006) 129(Part 11):2840-2855.
   PubMed Web of Science ®Google Scholar
• MASTERS CL, BEYREUTHER K: Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain (2006) 129(Part 11):2823-2839.
   PubMed Web of Science ®Google Scholar
• VARDY ER, HUSSAIN I, HOOPER NM: Emerging therapeutics for Alzheimer's disease. Expert Rev. Neurother. (2006) 6(5):695-704.
   PubMed Web of Science ®Google Scholar
• VERHOEFF NPLG: Acetylcholinergic neurotransmission and the β-amyloid cascade: implications for Alzheimer's disease. Expert Rev. Neurother. (2005) 5(2):277-284.
   PubMed Web of Science ®Google Scholar
• ERIKSEN JL, SAGI SA, SMITH TE et al.: NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest. (2003) 112(3):440-449.
   PubMed Web of Science ®Google Scholar
• LLEO A, BEREZOVSKA O, HERL L et al.: Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation. Nat. Med. (2004) 10(10):1065-1066.
   PubMed Web of Science ®Google Scholar
• GEERTS H: NC-531 (Neurochem). Curr. Opin. Investig. Drugs (2004) 5(1):95-100.
   PubMedGoogle Scholar
• FOX NC, BLACK RS, GILMAN S et al.: AN1792(QS-21)-201 study. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer's disease. Neurology (2005) 64(9):1563-1572.
   PubMed Web of Science ®Google Scholar
• DEMATTOS RB, BALES KR, CUMMINS DJ, PAUL SM, HOLTZMAN DM: Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 295(5563):2264-2267.
   PubMed Web of Science ®Google Scholar
• DODART JC, BALES KR, GANNON K et al.: Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. (2002) 5(5):452-457.
   PubMed Web of Science ®Google Scholar
• WILCOCK DM, ROJIANI A, ROSENTHAL A et al.: Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. (2004) 24(27):6144-6151.
   PubMed Web of Science ®Google Scholar
• MOHS RC, ROSEN WG, DAVIS KL: The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol. Bull. (1983) 19(3):448-550.
   PubMed Web of Science ®Google Scholar
• MCLAURIN J, KIERSTEAD ME, HAWKES CA et al.: Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. (2006) 12(7):801-808.
   PubMed Web of Science ®Google Scholar
• JANUS C, PEARSON J, MCLAURIN J et al.: Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408(6815):979-982.
   PubMed Web of Science ®Google Scholar
• MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408(6815):982-985.
   PubMed Web of Science ®Google Scholar
• HOCK C, KONIETZKO U, STREFFER JR et al.: Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 38(4):547-554.
   PubMed Web of Science ®Google Scholar
• SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400(6740):173-177.
   PubMed Web of Science ®Google Scholar
• NICOLL JA, WILKINSON D, HOLMES C, STEART P, MARKHAM H, WELLER RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report. Nat. Med. (2003) 9(4):448-452.
   PubMed Web of Science ®Google Scholar
• PFEIFER M, BONCRISTIANO S, BONDOLFI L et al.: Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science (2002) 298(5597:1379.
   PubMed Web of Science ®Google Scholar
• ORGOGOZO JM, GILMAN S, DARTIGUES JF et al.: Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology (2003) 61(1):46-54.
   PubMed Web of Science ®Google Scholar
• MORRIS JC, STORANDT M, MCKEEL DW JR et al.: Cerebral amyloid deposition and diffuse plaques in ‘normal’ ageing: evidence for presymptomatic and very mild Alzheimer's disease. Neurology (1996) 46(3):707-719.
   PubMed Web of Science ®Google Scholar
• HULETTE CM, WELSH-BOHMER KA, MURRAY MG, SAUNDERS AM, MASH DC, MCINTYRE LM: Neuropathological and neuropsychological changes in ‘normal’ ageing: evidence for preclinical Alzheimer's disease in cognitively normal individuals. J. Neuropathol. Exp. Neurol. (1998) 57(12):1168-1174.
   PubMed Web of Science ®Google Scholar
• PETERSEN RC: Mild cognitive impairment as a diagnostic entity. J. Intern. Med. (2004) 256(3):183-194.
   PubMed Web of Science ®Google Scholar
• NORDBERG A, FORSBERG A, ENGLER H et al.: Imaging of amyloid pathology in prodromal Alzheimer's disease. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):4.
   Google Scholar
• MINTUN MA, LAROSSA GN, SHELINE YI et al.: [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer's disease. Neurology (2006) 67(3):446-452.
   PubMed Web of Science ®Google Scholar
• AIZENSTEIN H, NEBES RD, SAXTON JA et al.: Amyloid imaging with Pittsburgh compound-B in non-demented elderly. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):1.
   Google Scholar
• DEVANAND DP, PARSEY R, PELTON GH et al.: PET amyloid imaging with [11C]6-)H-BTA-1 (PIB) in Alzheimer's disease, mild cognitive impairment, and healthy controls. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):6.
   Google Scholar
• RENTZ DM, ENG E, MORAN EK et al.: Mild memory impairments in normal sublects with high cognitive reserve are associated with amyloid deposition. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):2.
   Google Scholar
• ROWE CC, NG S, ACKERMANN U et al.: Imaging β-amyloid burden in ageing and dementia. Neurology (2007) 68(20):1718-1725.
   PubMed Web of Science ®Google Scholar
• RESNICK SM, ZHOU Y, AN Y et al.: Longitudinal cognitive change is associated with amyloid deposition measured by 11-C-PIB. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):3.
   Google Scholar
• VILLEMAGNE V, PIKE K, MARUFF P et al.: Amyloid burden in ageing subjects with and without cognitive decline. J. Nucl. Med. (2007) 48(Suppl. 2):P57.
   Google Scholar
• SPERLING R, LAVIOLETTE P, WHITE E et al.: Parietal amyloid deposition associated with impaired memory-related functional activity. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):5.
   Google Scholar
• KLUNK WE, PRICE JC, MATHIS CA et al.: Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. (2007) 27(23):6174-6184.
   PubMed Web of Science ®Google Scholar
• FAGAN AM, MINTUN MA, MACH RH et al.: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. (2006) 59(3):512-519.
   PubMed Web of Science ®Google Scholar
• JOHNSON KA, GREGAS M, BACKER JA et al.: Imaging of amyloid burden and distribution in cerebral amyloid angiography. Ann. Neurol. (2007) 62(3):229-234.
   PubMed Web of Science ®Google Scholar
• KLUNK WE, MATHIS CA, PRICE JC, LOPRESTI BJ, DEKOSKY ST: Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 129(Part 11):2805-2807.
   PubMed Web of Science ®Google Scholar
• EDISON P, RINNE J, ROWE C et al.: Amyloid imaging in AD, MCI, DLB, PDD, and FTD using 11C-PIB PET. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):17.
   Google Scholar
• EDISON P, ROWE CC, RINNE J et al.: Amyloid load in Lewy body dementia (LBD), Parkinson's disease dementia (PDD) and Parkinson's disease (PD) measured with 11C-PIB PET. Presentation at the April 28 – May 5, 2007, Annual Meeting of the American Academy of Neurology, Boston, MA, USA. Neurology (2007) 68(Suppl. 1):A98.
   Google Scholar
• DRZEZGA A, GRIMMER T, HENRIKSEN G et al.: Imaging of amyloid-plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):19.
   Google Scholar
• RABONOVICI GD, GORNO-TEMPINI ML, FURST AJ et al.: [11C]PIB PET in three variants of primary progressive aphasia. Human Amyloid Imaging Abstract Book. Boston, MA, USA (4 May 2007):20.
   Google Scholar
• KREISL C, RELKIN N, VALLABHAJOSULA S et al.: [11C]PIB imaging in primary progressive aphasia and Alzheimer's disease. J. Nucl. Med. (2007) 48(Suppl. 2):P58.
   Google Scholar
• CHECLER F, ALVES DA COSTA C, AYRAL E et al.: JLK inhibitors: isocoumarin compounds as putative probes to selectively target the gamma-secretase pathway. disease. Alzheimer Res. (2007) 2(3):327-334.
   Google Scholar
• PETIT A, PASINI A, ALVES DA COSTA C et al.: JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo. J Neurosci Res. (2003) 74(3):370-377.
   PubMed Web of Science ®Google Scholar